Response to apatinib and camrelizumab combined treatment in a radioiodine refractory differentiated thyroid cancer patient resistant to prior anti-angiogenic therapy: A case report and literature review

BACKGROUND: Patients with radioactive iodine refractory progressive (RAIR) differentiated thyroid cancer (DTC) often developed resistance after first-line therapy. Apatinib plus camrelizumab is a therapy with promising efficacy in patients with other malignant cancers. Herein, we presented a case of...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Jiayi, Zhang, Xin, Mu, Zhuanzhuan, Sun, Di, Sun, Yuqing, Lin, Yansong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9393697/
https://www.ncbi.nlm.nih.gov/pubmed/36003403
http://dx.doi.org/10.3389/fimmu.2022.943916

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9393697/
https://www.ncbi.nlm.nih.gov/pubmed/36003403
http://dx.doi.org/10.3389/fimmu.2022.943916

Ejemplares similares